Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

Ischemic lesions signal preventive needs in ICH patients

The finding of new ischemic lesions in patients with hypertensive intracerebral hemorrhage identifies patients at the greatest need of preventive therapy, research published in Neurology suggests.

8 Aug 2012

Children with negative TB skin test at high risk for mortality

Children with clinical signs of tuberculosis but with a negative tuberculin skin test result should not have treatment delayed, suggest study findings showing that false-negatives are common and associated with high mortality.

7 Aug 2012

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301).

7 Aug 2012

Soft implants preferable for nose augmentation

Soft implants are superior to hard implants for dorsal nasal augmentation, research shows.

6 Aug 2012

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

MRI useful for identifying bone lesions in diabetic feet

Identification of specific bone lesions in the feet of patients with diabetes can be achieved with magnetic resonance imaging, show study findings.

25 Jul 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck.

24 Jul 2012

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype.

24 Jul 2012

Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.

24 Jul 2012

Once-daily Gralise significantly reduces pain intensity in PHN patients

Depomed, Inc. today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN).

23 Jul 2012

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012

Chewing gum may relieve the pain of braces

Young adolescents and teens with fixed orthodontic appliances who chew gum report significantly less pain and impact of their braces than their peers who do not chew gum, report researchers from Sheffield in the UK.

23 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to treat posterior uveitis with pSivida's injectable sustained-release micro-insert.

20 Jul 2012

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Pfizer Inc. announced today that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation.

20 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

Edema News and Research

Further Reading

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Ischemic lesions signal preventive needs in ICH patients

Children with negative TB skin test at high risk for mortality

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

Soft implants preferable for nose augmentation

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

MRI useful for identifying bone lesions in diabetic feet

Regeneron reports total revenues of $304 million for second quarter 2012

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

Pfizer’s Lyrica does not affect reproductive function in healthy males

Once-daily Gralise significantly reduces pain intensity in PHN patients

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Chewing gum may relieve the pain of braces

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News